Skip to main content

Table 1 Considerations affecting access to new interventions

From: Implementing new health interventions in developing countries: why do we lose a decade or more?

 

Relevance to access

Considerations

Prior to regulatory approval

Availability & Affordability

Design of interventions specifically for the needs of DCs [31–37]

Adoption

Clinical studies to address questions unique to DCs [12, 38–42]

 

Requirements for international policy recommendations [43, 44]

 

Preparing for country decision-making processes [45]

After regulatory approval

Coordinated action

Coordination between stakeholders [16]

Availability

Alignment of intervention with the unique needs of developing country health systems [16, 18, 19, 23, 24]

 

Forecasting and manufacturing plans incorporating DCs, [16, 21]

 

Adapted procurement mechanisms [16, 21]

Affordability

Affordability, financing, & cost-effectiveness [16, 18, 19, 21–24, 27–30]

Adoption

Research aligned with policy-maker needs, including burden of disease addressed by an intervention [18, 21–24, 29]

 

Importance of international technical consensus and recommendations, including influence of neighboring countries [21, 23, 46]

 

Strengthened national processes, acceptability, and/or governance [17, 19–21, 26]

  1. Legend: Pubmed and Web of Science® databases were searched for full names or abbreviations of hepatitis B, Haemophilus influenzae type B, pneumococcal conjugate, rotavirus, insecticide-treated net, rapid diagnostic test, or artemisinin-based combination therapies AND (malaria or vaccin*) AND (develop* OR decision* OR policy* OR adopt* OR implement*).